PD-1合CTLA-4双免疫疗法对改善晚期乳腺癌近期疗效及远期预后的影响

来源期刊：广州医药 | 66-71 发布时间：2024-01-10 收稿时间：2025/11/13 18:28:20 阅读量：67

作者：: 王秋莹,

刘庆玲,

范春香,

李阁,

关键词：: 晚期乳腺癌程序性死亡受体1 细胞毒性T淋巴细胞相关蛋白4 双免疫疗法; advanced breast cancer programmed cell death protein-1 cytotoxic T lymphocyte-associated antigen-4 dual immunotherapy

DOI：: 10.3969/j.issn.1000-8535.2023.12.011

收稿时间：: 2023-05-10
修订日期：
接收日期：
引用总数：: 2

目的观察程序性死亡受体1（PD-1）联合细胞毒性T淋巴细胞相关蛋白4（CTLA-4）双免疫疗法对改善晚期乳腺癌近期疗效及远期预后的影响。方法选择2020年5月—2022年5月商丘市第一人民医院收治的124例晚期乳腺癌患者为研究对象,经随机数字表法将其分为对照组（60例）和观察组（64例）,对照组予以常规PD-1单抗免疫疗法治疗,观察组采用PD-1联合CTLA-4双免疫疗法治疗,比较2组患者治疗前后肿瘤标志物水平、治疗后病灶缓解情况,对所有患者开展为期1年随访,统计并对比2组的不良反应发生情况及远期生存情况。结果治疗前,2组患者的肿瘤标志物水平比较差异均无统计学意义（均P>0.05）;治疗后,观察组的癌胚抗原为（3.36±0.17）ng/mL,糖类抗原15-3为（25.33±5.28）U/mL,糖类抗原19-9为（38.77±5.62）U/mL,均低于对照组[（5.27±1.36）ng/mL、（28.44±5.18）U/mL、（41.25±5.46）U/mL,均P<0.05]。治疗后,观察组的完全缓解率为21.88%（14/64）,部分缓解率为31.25%（20/64）,病情稳定率为37.50%（24/64）,均高于对照组[8.33%（5/60）、13.33%（8/60）、23.33%（14/60）],肿瘤生长率为（30.27±5.18）%,肿瘤超进展率为6.25%（4/64）,均低于对照组[（33.49±5.32）%、18.33%（11/60）,均P<0.05]。治疗后,观察组的不良反应发生率为34.38%（22/64）,略高于对照组33.33%（20/60）,组间比较差异无统计学意义（P>0.05）;观察组的中位无进展生存期为（9.33±2.25）月,中位总生存期为（10.76±3.32）月,均高于对照组[（7.25±2.31）月、（7.41±1.62）月,均P<0.05]。结论 PD-1联合CTLA-4双免疫疗法能有效改善晚期乳腺癌的近期疗效及远期预后,此疗法未明显增加不良反应发生风险,安全性高。

Objective To observe the effect of programmed cell death protein-1（PD-1）combined with cytotoxic T lymphocyte-associated antigen-4（CTLA-4）dual immunotherapy on the short-term efficacy and long-term prognosis of advanced breast cancer．Methods A total of 124 patients with advanced breast cancer who were admitted to the First People's Hospital of Shangqiu City from May 2020 to May 2022 were selected as the research objects．They were randomly divided into the control group（60 cases）and the observation group（64 cases）by the method of random number table．The control group was treated with conventional PD-1 monoclonal antibody immunotherapy,and the observation group was treated with PD-1 combined with CTLA-4 double immunotherapy．The levels of tumor markers before and after treatment and the focal remission after treatment were compared between the two groups．All patients were followed up for one year,the incidence of adverse reactions and long-term survival between the two groups were compared．Results Before treatment,there was no statistically significant difference in the levels of tumor markers between two groups（all P>0.05）．After treatment,the carcino-embryonic antigen content of the observation group was（3.36±0.17）ng/mL,CA153 was（25.33±5.28）U/mL,and CA199 was（38.77±5.62）U/mL,which were lower than those of the control group [（5.27±1.36）ng/mL,（28.44±5.18）U/mL,（41.25±5.46）U/mL,all P<0.05]．After treatment,the complete remission rate of the observation group was 21.88%（14/64）,partial remission rate was 31.25%（20/64）,and stable disease rate was 37.50%（24/64）,all higher than those of the control group [8.33%（5/60）,13.33%（8/60）,23.33%（14/60）];tumor growth rate of the observation group was（30.27±5.18）%,hyper progressive disease rate was 6.25%（4/64）,both lower than those of the control group [（33.49±5.32）%,18.33%（11/60）,both P<0.05]．After treatment,the incidence of adverse reactions in the observation group was 34.38%（22/64）,slightly higher than that in the control group 33.33%（20/60）（P>0.05）．The median progression free survival of the observation group was（9.33±2.25）months,and the median overall survival was（10.76±3.32）months,both higher than those of the control group [（7.25±2.31）months and（7.41±1.62）months]（P<0.05）．Conclusions PD-1 combined with CTLA-4 dual immunotherapy can effectively improve the short-term efficacy and long-term prognosis of advanced breast cancer．This therapy does not significantly increase the risk of side effects,which is safe．

1、韩琳,谢刚,王燎,等.纳武利尤单抗联合伊匹木单抗治疗胸膜间皮瘤导致免疫相关性脑炎一例报道及文献复习[J].中国肿瘤生物治疗杂志,2022,29(11):1017-1020.

2、 LENZ H J,LONARDI S,ZAGONEL V,et al.Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer:Clinical update[J].J Clin Oncol,2020,38(4):11.

3、曾榃伦. 乳腺癌免疫治疗研究进展[J].中国肿瘤生物治疗杂志,2019,26(1):96-102.

4、郭宏果,刘军,程才,等.纳武利尤单抗联合含铂方案化疗治疗晚期三阴性乳腺癌对血清肿瘤标志物的影响及3年生存率观察[J].海南医学,2023,34(5):617-621.

5、张致远,夏凡,章真.放疗联合CTLA-4单抗的机制与临床研究进展[J].中华放射肿瘤学杂志,2021,30(9):975-978.

6、王爱红,赵菊梅,王明全.PD-1、CTLA-4和MMP9在伴或不伴淋巴结转移乳腺癌患者外泌体中的表达[J].现代免疫学,2019,39(2):110-114,144.

7、李培,吴炅.中国乳腺癌外科治疗现状和新趋势[J].中国肿瘤临床,2022,49(22):1151-1155.

8、 MA Y,ZONG H,WANG J,et al.Efficacy and safety of apatinib in treatment of gastric cancer:A real-world study[J].J Clin Oncol,2021,39(3_suppl):182.

9、 TAN A C,MCCRARY J M,PARK S B,et al.Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade[J].Support Care Cancer,2019,27(12):4771-4777.

10、杨宏,李皓静,罗丹阳,等.肿瘤免疫治疗超进展的研究和展望[J].中南医学科学杂志,2022,50(2):297-301.

11、 SJOQUIST K M,MARTIN A,PAVLAKIS N,et.al.Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer[J].J Cancer Res Clin Oncol,2023,149(8):4959-4965.

12、唐尧,万永慧,周焓,等.女性乳腺癌术后化疗患者需求现状及影响因素分析[J].中国医药导报,2022,19(20):45-48.

13、中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609-679.

14、 SANTONI M,ROMAGMOLI E,SALADINO T,et.al.Triple negative breast cancer:Key role of tumor-associated macrophages in regulating the activity of anti-PD-1/PD-L1 agents[J].Biochim Biophys Acta Rev Cancer,2018,1869(1):78-84.

15、张佳,李宏江.乳腺癌免疫检查点抑制剂研究进展[J].西部医学,2021,33(11):1708-1713.

16、贾岩,佟仲生.免疫检查点抑制剂在晚期三阴型乳腺癌治疗中的应用进展[J].山东医药,2022,62(2):112-115.

17、焦得闯,刘真真,刘荫华.中国乳腺癌改良根治术临床实践指南(2022版)[J].中国实用外科杂志,2022,42(2):128-131.

18、雷少元,郑荣寿,张思维,等.乳腺癌发病率和死亡率的全球模式:一项基于人群的2000—2020年肿瘤登记数据分析研究[J].癌症,2022,41(7):324-335.

1、叶汉挹.抗肿瘤植物来源活性miRNA及其联合化药治疗乳腺癌的研究[D].北京协和医学院,2024.DOI:10.27648/d.cnki.gzxhu.2024.001118.

2、陈妙玲,韩玉贞.PD-L1与肿瘤相关巨噬细胞在乳腺癌中的研究进展[J].国际医药卫生导报,2024,30(05):732-735.